Plague Outbreak in Siberia Boosts These Three Pharmaceutical Stocks

A plague outbreak in Siberia has triggered global biosecurity alerts, with analysts identifying three pharmaceutical stocks positioned to benefit from the resulting surge in biodefense spending. Following a researcher's fatal exposure to Yersinia pestis in the Irkutsk region, Russian authorities quarantined hospitals and isolated nearly 200 contacts. The incident has accelerated federal procurement and stockpiling of medical countermeasures, creating potential short-term momentum for companies like Emergent BioSolutions, Spero Therapeutics, and Innoviva. Emergent BioSolutions supplies anthrax and smallpox treatments to national stockpiles, while Spero focuses on drug-resistant gram-negative bacteria and Innoviva markets the FDA-approved antibiotic XACDURO. Analysts note these firms could gain from government contracts, though risks include regulatory delays and shifting federal priorities.